Eleven Biotherapeutics major shareholder Jafco Super V3 Investment Limi Sells 2,000 Shares (EBIO)
Eleven Biotherapeutics (NASDAQ:EBIO) major shareholder Jafco Super V3 Investment Limi unloaded 2,000 shares of the company’s stock on the open market in a transaction that occurred on Tuesday, August 26th. The stock was sold at an average price of $11.54, for a total transaction of $23,080.00. Following the transaction, the insider now directly owns 2,119,526 shares of the company’s stock, valued at approximately $24,459,330. The sale was disclosed in a document filed with the SEC, which is available at this link. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
Shares of Eleven Biotherapeutics (NASDAQ:EBIO) traded up 1.94% on Friday, hitting $11.05. 3,405 shares of the company’s stock traded hands. Eleven Biotherapeutics has a 1-year low of $9.502 and a 1-year high of $19.333. The stock has a 50-day moving average of $11.64 and a 200-day moving average of $12.92. The company’s market cap is $170.1 million.
Eleven Biotherapeutics (NASDAQ:EBIO) last posted its quarterly earnings results on Wednesday, August 13th. The company reported ($0.51) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.47) by $0.04. Analysts expect that Eleven Biotherapeutics will post $-1.84 EPS for the current fiscal year.
Eleven Biotherapeutics, Inc, is a United States-based company, which develops protein-based biotherapeutics.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.